Suzanne E Wardell
Assistant Research Professor of Pharmacology & Cancer Biology
Throughout my career in science, my work has focused in aspects of steroid hormone (progesterone, estrogen, or androgen) receptor activity in breast and prostate cancers. These interests include not only mechanistic studies of receptor activity in treatment naive tumors, but also the role of these receptors in the evolution of resistance to current therapies.
Despite the development of improved therapies, breast cancer remains a leading cause of mortality in women. While a majority of breast cancers are estrogen receptor (ER) positive and respond to endocrine therapies such as tamoxifen or aromatase inhibitors, as many as 50% of patients experience relapse and progression. Recent data has confirmed continued reliance of these cancers on ER signaling, validating this receptor as a therapeutic target even in a relapsed/metastatic setting. The focus of a majority of my work in breast cancer has been the mechanistic evaluation of methods to target ER activity in this setting of resistance, either through the development of improved receptor antagonists or through the identification of targets downstream of, or impinging upon, ER activity that can serve as secondary targets in this setting.
Similarly, the androgen receptor (AR) remains a therapeutic target in prostate cancer throughout treatment progression to end stage prostate cancer. Although several AR antagonists have been developed and approved for the treatment of prostate cancer, AR overexpression, as well as mutation and/or truncation, are observed clinically and have been shown mechanistically to render the current AR antagonists ineffective in the advanced prostate cancer setting. As with our work in breast cancer, we have identified pathways downstream of AR that are essential to prostate cancer progression, and our current work is intended to devise treatment regimens that will be effective in lieu of, or together with, AR antagonists.
In my role as a research assistant professor, I have conducted several animal studies evaluating next-to-clinic therapeutics in clinically predictive models of advanced breast and prostate cancer that I have developed throughout the past several years of studies. The entry of some of these therapeutics, or of mechanistically related molecules, into clinical trials in these patient populations validates this approach.
Despite the development of improved therapies, breast cancer remains a leading cause of mortality in women. While a majority of breast cancers are estrogen receptor (ER) positive and respond to endocrine therapies such as tamoxifen or aromatase inhibitors, as many as 50% of patients experience relapse and progression. Recent data has confirmed continued reliance of these cancers on ER signaling, validating this receptor as a therapeutic target even in a relapsed/metastatic setting. The focus of a majority of my work in breast cancer has been the mechanistic evaluation of methods to target ER activity in this setting of resistance, either through the development of improved receptor antagonists or through the identification of targets downstream of, or impinging upon, ER activity that can serve as secondary targets in this setting.
Similarly, the androgen receptor (AR) remains a therapeutic target in prostate cancer throughout treatment progression to end stage prostate cancer. Although several AR antagonists have been developed and approved for the treatment of prostate cancer, AR overexpression, as well as mutation and/or truncation, are observed clinically and have been shown mechanistically to render the current AR antagonists ineffective in the advanced prostate cancer setting. As with our work in breast cancer, we have identified pathways downstream of AR that are essential to prostate cancer progression, and our current work is intended to devise treatment regimens that will be effective in lieu of, or together with, AR antagonists.
In my role as a research assistant professor, I have conducted several animal studies evaluating next-to-clinic therapeutics in clinically predictive models of advanced breast and prostate cancer that I have developed throughout the past several years of studies. The entry of some of these therapeutics, or of mechanistically related molecules, into clinical trials in these patient populations validates this approach.
Current Appointments & Affiliations
- Assistant Research Professor of Pharmacology & Cancer Biology, Pharmacology & Cancer Biology, Basic Science Departments 2015
Contact Information
- Box 3813 Med Ctr, Durham, NC 27710
- Lsrc. C-248, Durham, NC 27710
-
suzanne.wardell@duke.edu
(919) 681-8401
- Background
-
Education, Training, & Certifications
- Ph.D., University of Colorado School of Medicine 2004
- B.Sc., Washington State University 1998
- Expertise
-
Subject Headings
- Research
-
Selected Grants
- Elucidation of the mechanisms by which cells recognize and respond to different levels of androgens awarded by National Institutes of Health 2022 - 2027
- Cancer cell intrinsic and extrinsic actions of steroid hormones in breast tumors awarded by Department of Defense 2018 - 2023
- HOXB13 as a therapeutic target in prostate cancer awarded by Prostate Cancer Foundation 2020 - 2023
- Regulatory principles of the Warburg Effect awarded by American Cancer Society, Inc. 2017 - 2022
- Evaluation of estrogen receptor as a therapeutic target in melanoma, lung and colorectal cancer models awarded by Zentalis Pharmaceuticals 2020 - 2022
- Identification of Novel Targets in Treatment Resistant Prostate Cancer awarded by Celgene Corporation 2017 - 2022
- Role of ER RNA Binding Domain in Breast Cancer awarded by Ribometrix LLC 2022
- Evaluation of SGK as a therapeutic target in models of breast and prostate cancer awarded by LQT Therapeutics 2021 - 2022
- Evaluation of novel CDK4/6/9 inhibitors in triple negative breast cancer awarded by SPV Therapeutics, Inc 2020
- Developing in vivo active probes for CAMKK2 to treat cancer awarded by University of North Carolina - Chapel Hill 2017 - 2020
- Targeting precursor neural (N)-cadherin to eliminate chemotherapy-resistant triple-negative breast tumor cells awarded by Department of Defense 2017 - 2020
- Targeting differential apoptosis regulation in triple negative breast cancer awarded by Department of Defense 2016 - 2019
- Evaluation of G1 antiestrogens in models of estrogen action awarded by G1 Therapeutics Inc. 2018 - 2019
- Targeting the synthetic essential kinases of breast cancers awarded by Department of Defense 2015 - 2018
- Evaluating the efficacy of targeting the AGR2 axis in breast and prostate cancer awarded by Viba Therapeutics 2017 - 2018
- Evaluation of the SERD XR5-28 in models of estrogen action awarded by G1 Therapeutics Inc. 2016 - 2017
- Evaluation of G1T38 and SERD XR5-28 in hormone refractory breast cancer awarded by G1 Therapeutics Inc. 2016 - 2017
- Determination of the antiandrogenic properties of VT-464 in models of CRPC awarded by Innocrin Pharmaceutical, Inc. 2016 - 2017
- Evaluation of the therapeutic potential of combining VT464 and G1T38 in treatment-resistant prostate and breast cancer models awarded by Innocrin Pharmaceutical, Inc. 2016 - 2017
- Targeting the CDK 4/6 axis in Castration Resistant Prostate Cancer awarded by G1 Therapeutics Inc. 2015 - 2016
- Evaluation of VT-464 in AR positive and ER positive breast cancer models awarded by Innocrin Pharmaceutical, Inc. 2015 - 2016
- Androgen receptor degradation as a therapeutic modality in castrate resistant prostate cancer awarded by Arvinas Inc. 2015
- Determination of the antiandrogenic properties of VT-464, a novel CYP17 lyase inhibitor awarded by Viamet Pharmaceuticals 2014 - 2015
- Molecular pharmacology of bazedoxifene and pipendoxifene in breast cancer awarded by Pfizer, Inc. 2013 - 2014
-
External Relationships
- Radius Health
- SPV Therapeutics, Inc.
- Zentalis Pharmaceuticals (formerly Zeno Pharma)
- Publications & Artistic Works
-
Selected Publications
-
Academic Articles
-
Russell, Shonagh, Felicia Lim, Pamela N. Peters, Suzanne E. Wardell, Regina Whitaker, Ching-Yi Chang, Rebecca A. Previs, and Donald P. McDonnell. “Development and Characterization of a Luciferase Labeled, Syngeneic Murine Model of Ovarian Cancer.” Cancers (Basel) 14, no. 17 (August 30, 2022). https://doi.org/10.3390/cancers14174219.Full Text Open Access Copy Link to Item
-
Haines, Corinne N., Suzanne E. Wardell, and Donald P. McDonnell. “Current and emerging estrogen receptor-targeted therapies for the treatment of breast cancer.” Essays Biochem 65, no. 6 (December 17, 2021): 985–1001. https://doi.org/10.1042/EBC20200174.Full Text Link to Item
-
Chakraborty, Binita, Jovita Byemerwa, Jonathan Shepherd, Corinne N. Haines, Robert Baldi, Weida Gong, Wen Liu, et al. “Inhibition of estrogen signaling in myeloid cells increases tumor immunity in melanoma.” J Clin Invest 131, no. 23 (December 1, 2021). https://doi.org/10.1172/JCI151347.Full Text Open Access Copy Link to Item
-
Joh, Daniel Y., Jacob T. Heggestad, Shengwei Zhang, Gray R. Anderson, Jayanta Bhattacharyya, Suzanne E. Wardell, Simone A. Wall, et al. “Author Correction: Cellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates.” Npj Breast Cancer 7, no. 1 (September 17, 2021): 126. https://doi.org/10.1038/s41523-021-00335-4.Full Text Link to Item
-
Lowder, Leah L., Matthew Powell, Sean E. Miller, Rigel J. Kishton, Charles B. Kelly, Connor B. Cribb, Kelly Mastro-Kishton, et al. “Mechanistic Investigation of Site-specific DNA Methylating Agents Targeting Breast Cancer Cells.” J Med Chem 64, no. 17 (September 9, 2021): 12651–69. https://doi.org/10.1021/acs.jmedchem.1c00615.Full Text Link to Item
-
Joh, Daniel Y., Jacob T. Heggestad, Shengwei Zhang, Gray R. Anderson, Jayanta Bhattacharyya, Suzanne E. Wardell, Simone A. Wall, et al. “Cellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates.” Npj Breast Cancer 7, no. 1 (July 2021): 85. https://doi.org/10.1038/s41523-021-00290-0.Full Text
-
McDonnell, Donald P., Suzanne E. Wardell, Ching-Yi Chang, and John D. Norris. “Next-Generation Endocrine Therapies for Breast Cancer.” J Clin Oncol 39, no. 12 (April 20, 2021): 1383–88. https://doi.org/10.1200/JCO.20.03565.Full Text Link to Item
-
Andreano, Kaitlyn J., Jennifer G. Baker, Sunghee Park, Rachid Safi, Sandeep Artham, Steffi Oesterreich, Rinath Jeselsohn, et al. “The Dysregulated Pharmacology of Clinically Relevant ESR1 Mutants is Normalized by Ligand-activated WT Receptor.” Mol Cancer Ther 19, no. 7 (July 2020): 1395–1405. https://doi.org/10.1158/1535-7163.MCT-19-1148.Full Text Link to Item
-
Andreano, Kaitlyn J., Suzanne E. Wardell, Jennifer G. Baker, Taylor K. Desautels, Robert Baldi, Christina A. Chao, Kendall A. Heetderks, et al. “G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer.” Breast Cancer Res Treat 180, no. 3 (April 2020): 635–46. https://doi.org/10.1007/s10549-020-05575-9.Full Text Link to Item
-
Wardell, Suzanne E., Alexander P. Yllanes, Christina A. Chao, Yeeun Bae, Kaitlyn J. Andreano, Taylor K. Desautels, Kendall A. Heetderks, Jeremy T. Blitzer, John D. Norris, and Donald P. McDonnell. “Correction to: Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy.” Breast Cancer Res Treat 179, no. 3 (February 2020): 769. https://doi.org/10.1007/s10549-019-05498-0.Full Text Link to Item
-
Wardell, Suzanne E., Alexander P. Yllanes, Christina A. Chao, Yeeun Bae, Kaitlyn J. Andreano, Taylor K. Desautels, Kendall A. Heetderks, Jeremy T. Blitzer, John D. Norris, and Donald P. McDonnell. “Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy.” Breast Cancer Res Treat 179, no. 1 (January 2020): 67–77. https://doi.org/10.1007/s10549-019-05454-y.Full Text Link to Item
-
Cocce, Kimberly J., Jeff S. Jasper, Taylor K. Desautels, Logan Everett, Suzanne Wardell, Thomas Westerling, Robert Baldi, et al. “The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer.” Cell Rep 29, no. 4 (October 22, 2019): 889-903.e10. https://doi.org/10.1016/j.celrep.2019.09.032.Full Text Link to Item
-
Manzari, Mandana T., Gray R. Anderson, Kevin H. Lin, Ryan S. Soderquist, Merve Çakir, Mitchell Zhang, Chandler E. Moore, et al. “Genomically informed small-molecule drugs overcome resistance to a sustained-release formulation of an engineered death receptor agonist in patient-derived tumor models.” Sci Adv 5, no. 9 (September 2019): eaaw9162. https://doi.org/10.1126/sciadv.aaw9162.Full Text Link to Item
-
Wardell, Suzanne E., John D. Norris, and Donald P. McDonnell. “Targeting mutant estrogen receptors.” Elife 8 (January 16, 2019). https://doi.org/10.7554/eLife.44181.Full Text Link to Item
-
Puyang, Xiaoling, Craig Furman, Guo Zhu Zheng, Zhenhua J. Wu, Deepti Banka, Kiran Aithal, Sergei Agoulnik, et al. “Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERαWT and ERαMUT Breast Cancer.” Cancer Discov 8, no. 9 (September 2018): 1176–93. https://doi.org/10.1158/2159-8290.CD-17-1229.Full Text Link to Item
-
Anderson, Gray R., Suzanne E. Wardell, Merve Cakir, Catherine Yip, Yeong-Ran Ahn, Moiez Ali, Alexander P. Yllanes, Christina A. Chao, Donald P. McDonnell, and Kris C. Wood. “Dysregulation of mitochondrial dynamics proteins are a targetable feature of human tumors.” Nat Commun 9, no. 1 (April 26, 2018): 1677. https://doi.org/10.1038/s41467-018-04033-x.Full Text Link to Item
-
McLeod, Abigail B., James P. Stice, Suzanne E. Wardell, Holly M. Alley, Ching-Yi Chang, and Donald P. McDonnell. “Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.” Prostate 78, no. 4 (March 2018): 266–77. https://doi.org/10.1002/pros.23467.Full Text Link to Item
-
Baek, Amy E., Yen-Rei A. Yu, Sisi He, Suzanne E. Wardell, Ching-Yi Chang, Sanghoon Kwon, Ruchita V. Pillai, et al. “The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells.” Nat Commun 8, no. 1 (October 11, 2017): 864. https://doi.org/10.1038/s41467-017-00910-z.Full Text Link to Item
-
Liberti, Maria V., Ziwei Dai, Suzanne E. Wardell, Joshua A. Baccile, Xiaojing Liu, Xia Gao, Robert Baldi, et al. “A Predictive Model for Selective Targeting of the Warburg Effect through GAPDH Inhibition with a Natural Product.” Cell Metab 26, no. 4 (October 3, 2017): 648-659.e8. https://doi.org/10.1016/j.cmet.2017.08.017.Full Text Link to Item
-
Tang, X., C. -. K. Ding, J. Wu, J. Sjol, S. Wardell, I. Spasojevic, D. George, et al. “Cystine addiction of triple-negative breast cancer associated with EMT augmented death signaling.” Oncogene 36, no. 30 (July 27, 2017): 4235–42. https://doi.org/10.1038/onc.2016.394.Full Text Link to Item
-
Tang, X., C. -. K. Ding, J. Wu, J. Sjol, S. Wardell, I. Spasojevic, D. George, et al. “Cystine addiction of triple-negative breast cancer associated with EMT augmented death signaling.” Oncogene 36, no. 30 (July 27, 2017): 4379. https://doi.org/10.1038/onc.2017.192.Full Text Link to Item
-
Anderson, Grace R., Peter S. Winter, Kevin H. Lin, Daniel P. Nussbaum, Merve Cakir, Elizabeth M. Stein, Ryan S. Soderquist, et al. “A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution.” Cell Rep 20, no. 4 (July 25, 2017): 999–1015. https://doi.org/10.1016/j.celrep.2017.07.006.Full Text Link to Item
-
Stice, James P., Suzanne E. Wardell, John D. Norris, Alexander P. Yllanes, Holly M. Alley, Victoria O. Haney, Hannah S. White, et al. “CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC.” Mol Cancer Res 15, no. 6 (June 2017): 660–69. https://doi.org/10.1158/1541-7786.MCR-17-0028.Full Text Link to Item
-
Norris, John D., Stephanie J. Ellison, Jennifer G. Baker, David B. Stagg, Suzanne E. Wardell, Sunghee Park, Holly M. Alley, et al. “Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer.” J Clin Invest 127, no. 6 (June 1, 2017): 2326–38. https://doi.org/10.1172/JCI87328.Full Text Link to Item
-
Anderson, Gray R., Suzanne E. Wardell, Merve Cakir, Lorin Crawford, Jim C. Leeds, Daniel P. Nussbaum, Pallavi S. Shankar, et al. “PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.” Sci Transl Med 8, no. 369 (December 14, 2016): 369ra175. https://doi.org/10.1126/scitranslmed.aae0348.Full Text Open Access Copy Link to Item
-
Pollock, Julie A., Suzanne E. Wardell, Alexander A. Parent, David B. Stagg, Stephanie J. Ellison, Holly M. Alley, Christina A. Chao, et al. “Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer.” Nat Chem Biol 12, no. 10 (October 2016): 795–801. https://doi.org/10.1038/nchembio.2131.Full Text Link to Item
-
Wood, Kris C., Grace R. Anderson, Suzanne E. Wardell, Jeff S. Jasper, Elizabeth M. Stein, Colin A. Martz, Holly M. Alley, et al. “Identification and Therapeutic Inhibition of Pathways Driving Resistance to Targeted Breast Cancer Therapies.” Journal of Womens Health 25, no. 9 (September 1, 2016): 976–976.Link to Item
-
Wardell, Suzanne E., Matthew J. Ellis, Holly M. Alley, Koleen Eisele, Todd VanArsdale, Stephen G. Dann, Kim T. Arndt, et al. “Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.” Clin Cancer Res 21, no. 22 (November 15, 2015): 5121–30. https://doi.org/10.1158/1078-0432.CCR-15-0360.Full Text Link to Item
-
Wardell, Suzanne E., Erik R. Nelson, Christina A. Chao, Holly M. Alley, and Donald P. McDonnell. “Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader.” Endocr Relat Cancer 22, no. 5 (October 2015): 713–24. https://doi.org/10.1530/ERC-15-0287.Full Text Link to Item
-
McDonnell, Donald P., Suzanne E. Wardell, and John D. Norris. “Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer.” J Med Chem 58, no. 12 (June 25, 2015): 4883–87. https://doi.org/10.1021/acs.jmedchem.5b00760.Full Text Link to Item
-
Martz, Colin A., Kathleen A. Ottina, Katherine R. Singleton, Jeff S. Jasper, Suzanne E. Wardell, Ashley Peraza-Penton, Gray R. Anderson, et al. “Systematic identification of signaling pathways with potential to confer anticancer drug resistance.” Sci Signal 7, no. 357 (December 23, 2014): ra121. https://doi.org/10.1126/scisignal.aaa1877.Full Text Link to Item
-
Wright, Tricia M., Suzanne E. Wardell, Jeff S. Jasper, James P. Stice, Rachid Safi, Erik R. Nelson, and Donald P. McDonnell. “Delineation of a FOXA1/ERα/AGR2 regulatory loop that is dysregulated in endocrine therapy-resistant breast cancer.” Mol Cancer Res 12, no. 12 (December 2014): 1829–39. https://doi.org/10.1158/1541-7786.MCR-14-0195.Full Text Link to Item
-
Wardell, Suzanne E., Erik R. Nelson, and Donald P. McDonnell. “From empirical to mechanism-based discovery of clinically useful Selective Estrogen Receptor Modulators (SERMs).” Steroids 90 (November 2014): 30–38. https://doi.org/10.1016/j.steroids.2014.07.013.Full Text Link to Item
-
McDonnell, Donald P., Sunghee Park, Matthew T. Goulet, Jeff Jasper, Suzanne E. Wardell, Ching-Yi Chang, John D. Norris, John R. Guyton, and Erik R. Nelson. “Obesity, cholesterol metabolism, and breast cancer pathogenesis.” Cancer Res 74, no. 18 (September 15, 2014): 4976–82. https://doi.org/10.1158/0008-5472.CAN-14-1756.Full Text Link to Item
-
Nelson, Erik R., Suzanne E. Wardell, Jeff S. Jasper, Sunghee Park, Sunil Suchindran, Matthew K. Howe, Nicole J. Carver, et al. “27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology.” Science 342, no. 6162 (November 29, 2013): 1094–98. https://doi.org/10.1126/science.1241908.Full Text Link to Item
-
Wardell, Suzanne E., Erik R. Nelson, Christina A. Chao, and Donald P. McDonnell. “Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease.” Clin Cancer Res 19, no. 9 (May 1, 2013): 2420–31. https://doi.org/10.1158/1078-0432.CCR-12-3771.Full Text Link to Item
-
Nelson, Erik R., Suzanne E. Wardell, and Donald P. McDonnell. “The molecular mechanisms underlying the pharmacological actions of estrogens, SERMs and oxysterols: implications for the treatment and prevention of osteoporosis.” Bone 53, no. 1 (March 2013): 42–50. https://doi.org/10.1016/j.bone.2012.11.011.Full Text Link to Item
-
Nelson, Erik Russell, Suzanne E. Wardell, Matthew K. Howe, Nicole J. Carver, Michihisa Umetani, and Donald P. McDonnell. “Abstract PR3: The cholesterol metabolite 27-hydroxycholesterol increases breast cancer tumor growth and metastasis.” Cancer Research 73, no. 3_Supplement (February 1, 2013): PR3–PR3. https://doi.org/10.1158/1538-7445.tim2013-pr3.Full Text
-
Wardell, S. E., D. P. McDonnell, and E. R. Nelson. “Regulation of Bone Cell Function by Estrogens,” January 1, 2013, 329–44. https://doi.org/10.1016/B978-0-12-415853-5.00014-5.Full Text
-
Wardell, Suzanne E., Dmitri Kazmin, and Donald P. McDonnell. “Research resource: Transcriptional profiling in a cellular model of breast cancer reveals functional and mechanistic differences between clinically relevant SERM and between SERM/estrogen complexes.” Mol Endocrinol 26, no. 7 (July 2012): 1235–48. https://doi.org/10.1210/me.2012-1031.Full Text Link to Item
-
Wardell, Suzanne E., Jeffrey R. Marks, and Donald P. McDonnell. “The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy.” Biochem Pharmacol 82, no. 2 (July 15, 2011): 122–30. https://doi.org/10.1016/j.bcp.2011.03.031.Full Text Link to Item
-
McDonnell, Donald P., and Suzanne E. Wardell. “The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer.” Curr Opin Pharmacol 10, no. 6 (December 2010): 620–28. https://doi.org/10.1016/j.coph.2010.09.007.Full Text Link to Item
-
Wardell, Suzanne E., Ramesh Narayanan, Nancy L. Weigel, and Dean P. Edwards. “Partial agonist activity of the progesterone receptor antagonist RU486 mediated by an amino-terminal domain coactivator and phosphorylation of serine400.” Mol Endocrinol 24, no. 2 (February 2010): 335–45. https://doi.org/10.1210/me.2008-0081.Full Text Link to Item
-
Wardell, Suzanne E., Olga R. Ilkayeva, Heather L. Wieman, Daniel E. Frigo, Jeffrey C. Rathmell, Christopher B. Newgard, and Donald P. McDonnell. “Glucose metabolism as a target of histone deacetylase inhibitors.” Mol Endocrinol 23, no. 3 (March 2009): 388–401. https://doi.org/10.1210/me.2008-0179.Full Text Link to Item
-
Lu, Nick Z., Suzanne E. Wardell, Kerry L. Burnstein, Donald Defranco, Peter J. Fuller, Vincent Giguere, Richard B. Hochberg, et al. “International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors.” Pharmacol Rev 58, no. 4 (December 2006): 782–97. https://doi.org/10.1124/pr.58.4.9.Full Text Link to Item
-
Wardell, Suzanne E., Stanley C. Kwok, Lori Sherman, Robert S. Hodges, and Dean P. Edwards. “Regulation of the amino-terminal transcription activation domain of progesterone receptor by a cofactor-induced protein folding mechanism.” Mol Cell Biol 25, no. 20 (October 2005): 8792–8808. https://doi.org/10.1128/MCB.25.20.8792-8808.2005.Full Text Link to Item
-
Wardell, Suzanne E., and Dean P. Edwards. “Mechanisms controlling agonist and antagonist potential of selective progesterone receptor modulators (SPRMs).” Semin Reprod Med 23, no. 1 (February 2005): 9–21. https://doi.org/10.1055/s-2005-864030.Full Text Link to Item
-
Wardell, Suzanne E., Viroj Boonyaratanakornkit, James S. Adelman, Ami Aronheim, and Dean P. Edwards. “Jun dimerization protein 2 functions as a progesterone receptor N-terminal domain coactivator.” Mol Cell Biol 22, no. 15 (August 2002): 5451–66. https://doi.org/10.1128/MCB.22.15.5451-5466.2002.Full Text Link to Item
-
-
Conference Papers
-
Sammons, Sarah, Grace Anderson, Suzanne Wardell, Donald P. McDonnell, Paul Kelly Marcom, and Kris Wood. “Combination mTORC1/2 and BCL- XL inhibition in endocrine and CDK4/6-resistant estrogen receptor-positive breast cancer.” In Journal of Clinical Oncology, 37:e14653–e14653. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.e14653.Full Text
-
Liberti, Maria V., Ziwei Dai, Suzanne E. Wardell, Joshua A. Baccile, Xiaojing Liu, Xia Gao, Robert Baldi, et al. “Abstract 5496: A predictive model for selective targeting of the Warburg effect through GAPDH inhibition with a natural product.” In Cancer Research, 78:5496–5496. American Association for Cancer Research (AACR), 2018. https://doi.org/10.1158/1538-7445.am2018-5496.Full Text
-
Yao, ZhongKe, Suzanne Wardell, Ivan Spasojevic, John Norris, John Katzenellenbogen, Donald McDonnell, and Jatinder S. Josan. “Abstract 1805: Development of a selective androgen receptor degrader (SARD) for treatment of castration-resistant prostate cancer.” In Cancer Research, 78:1805–1805. American Association for Cancer Research (AACR), 2018. https://doi.org/10.1158/1538-7445.am2018-1805.Full Text
-
Yao, Zhong-Ke, Suzanne Wardell, Ivan Spasojevic, John Norris, John Katzenellenbogen, Donald McDonnell, and Jatinder Josan. “Discovery of a selective androgen receptor degrader (SARD) for treatment of castration-resistant prostate cancer.” In Abstracts of Papers of the American Chemical Society, Vol. 254. AMER CHEMICAL SOC, 2017.Link to Item
-
McDonnell, Donald, Kimberly Cocce, Suzanne Wardell, and John Norris. “SERMs and SERDs as the cornerstone of endocrine therapy in ER alpha-positive breast cancer.” In Abstracts of Papers of the American Chemical Society, Vol. 252. AMER CHEMICAL SOC, 2016.Link to Item
-
Link, Jennifer, Sunhee Hwang, Jonathan Burg, Suzanne Wardell, and Dewey McCafferty. “Targeting protein-protein interactions for disruption of KDM1A (LSD1) complexes.” In Abstracts of Papers of the American Chemical Society, Vol. 251. AMER CHEMICAL SOC, 2016.Link to Item
-
Ellison, S. J., J. D. Norris, S. Wardell, J. R. Eisner, W. J. Hoekstra, D. B. Stagg, H. M. Alley, W. R. Moore, and D. P. McDonnell. “Abstract P3-14-04: Effects of the dual selective CYP17 lyase inhibitor and androgen receptor (AR) antagonist, VT-464, on AR+ and ER+ tumor models in vitro and in vivo.” In Cancer Research, Vol. 76. American Association for Cancer Research (AACR), 2016. https://doi.org/10.1158/1538-7445.sabcs15-p3-14-04.Full Text
-
Moore, William R., John D. Norris, Suzanne Wardell, Joel Robert Eisner, William J. Hoekstra, Robert J. Schotzinger, and Donald P. McDonnell. “Direct effects of the selective CYP17 lyase (L) inhibitor, VT-464, on the androgen receptor (AR) and its oral activity in an F876L tumor mouse xenograft model.” In Journal of Clinical Oncology, 33:263–263. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.7_suppl.263.Full Text
-
Katzenellenbogen, John A., Julie A. Pollock, Alexander A. Parent, Suzanne Elizabeth Wardell, Donald P. McDonnell, and John D. Norris. “Structurally Novel Antagonists of Androgen Receptors with Elevated Potency for Antiandrogen-Resistant Receptor Mutants in Prostate Cancer: Tetra-Aryl-Substituted Cyclobutanes.” In Endocrine Reviews, Vol. 35. ENDOCRINE SOC, 2014.Link to Item
-
Katzenellenbogen, John A., Julie A. Pollock, Alexander A. Parent, Suzanne Elizabeth Wardell, Donald P. McDonnell, and John D. Norris. “Structurally Novel Antagonists of Androgen Receptors with Elevated Potency for Antiandrogen-Resistant Receptor Mutants in Prostate Cancer: Tetra-Aryl-Substituted Cyclobutanes.” In Endocrine Reviews, Vol. 35. ENDOCRINE SOC, 2014.Link to Item
-
Edwards, Dean P., Suzanne E. Wardell, and Viroj Boonyaratanakornkit. “Progesterone receptor interacting coregulatory proteins and cross talk with cell signaling pathways.” In J Steroid Biochem Mol Biol, 83:173–86, 2002. https://doi.org/10.1016/s0960-0760(02)00265-0.Full Text Link to Item
-
-
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.